Clinical

Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
 
Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
 
Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
 
Learn More

Luminex® Blog

The Faces of Luminex: Robin Murphy, Systems Integration

The Luminex R&D teams for hardware, software, reagents, and assays operate mostly independently—which means we need great scientists to pull each of these elements together and ensure a seamless user experience. For this, we rely on Robin Murphy, Scientist II, who has been part of our family since 2006.

Continue Reading >

xMAP® Technology Overview

 
Video Thumbnail  Clinical Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.  Read More Research & Applied Markets Our xMAP® Technology and its flexible, open-a

 

xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.

Watch more videos >

Luminex on Twitter


RT @IDSAInfo: As the U.S. enters peak #flu season, it’s never too late to get your flu shot, says IDSA member Flor Munoz, MD. #VaccinesWork…
h J R
RT @CDCFlu: New York City, Puerto Rico and 32 states are still experiencing high levels of #flu-like-illness, the latest CDC #FluView repor…
h J R

Latest News

January 12th
Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference

December 6th
Luminex Corporation Declares Fourth Quarter Cash Dividend

4 November
Luminex Corporation Reports Third Quarter 2019 Results and Submission of VERIGENE II Gastrointestinal Flex Assay to the FDA

Events

Swiss Flow Cytometry
5-7 February
Lausanne, Switzerland


Biomarkers
18-20 February
Manchester, UK